Men's Health

With this expansion, the platform now represents a comprehensive automated testosterone testing solution.

A recap of the FDA submissions and regulatory decisions in urology from April 2026.

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.

Akanksha Mehta, MD, MS, highlights key recommendations on pre-vasectomy counseling from the American Urological Association’s 2026 Vasectomy Guideline.

The following FAQ highlights key recommendations for urologists from the 2026 AUA Vasectomy Guideline.

A recap of the FDA submissions and regulatory decisions in urology from February 2026.

According to Alex Tatem, MD, misinformation online and aggressive marketing frequently push patients toward unregulated providers offering injectable silicone or other non-medical substances.

Tatem contrasts medically supervised treatments with rumored unsupervised or clandestine procedures.

Alex Tatem, MD, explains that hyaluronic acid penile injections add temporary, measurable girth by safely distributing a reversible filler within soft tissue, though outcomes depend heavily on technique and vary between individuals.

The conversation explores the growing role of at-home semen testing kits as screening tools, their advantages in accessibility and privacy, and their limitations compared with in-lab testing.

The sildenafil oral film is expected to be commercially available in the US in March 2026.

The results highlight the early clinical potential of the device for restoring erectile function post-prostatectomy.

The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.

As the year comes to a close, we revisit some of this year’s top content in men's health.

Exogenous testosterone therapy and fertility are fundamentally incompatible.

Regarding compounded testosterone products, Jesse N. Mills, MD, takes a balanced but cautious stance.

Mills warns that poorly justified combination regimens complicate downstream management for urologists.

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

Ibrahim explains the unique challenges men face after spinal cord injury, including neurogenic erectile dysfunction, ejaculatory dysfunction, and particularly the distinctive sperm abnormalities seen in this population.

In a panel meeting convened by the FDA, experts urged the agency to revise the current classification and indication for testosterone replacement therapy in men.

Another critical research need involves understanding the effects of exogenous testosterone.

Leila Momtazi-Mar notes that although some studies suggest a decline in retrieval rates after age 40, this association remains preliminary.